Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Declines By 17.5%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 121,000 shares, a decrease of 17.5% from the February 28th total of 146,700 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 322,600 shares, the days-to-cover ratio is currently 0.4 days.

Sensei Biotherapeutics Stock Performance

Shares of SNSE stock traded down $0.01 during trading on Wednesday, hitting $0.34. 279,742 shares of the company were exchanged, compared to its average volume of 911,690. The firm has a market capitalization of $8.48 million, a price-to-earnings ratio of -0.28 and a beta of 0.16. The business’s 50-day simple moving average is $0.46 and its 200 day simple moving average is $0.49. Sensei Biotherapeutics has a twelve month low of $0.25 and a twelve month high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, meeting analysts’ consensus estimates of ($0.27). On average, equities analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI lifted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the quarter. National Bank of Canada FI owned about 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNSE. Oppenheimer lifted their target price on shares of Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a research report on Friday, March 28th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research report on Friday, March 28th.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.